Biotechnology Ultrasector Net Asset vs. Price To Earning
| BIPIX Fund | USD 61.91 0.88 1.40% |
For Biotechnology Ultrasector profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biotechnology Ultrasector to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biotechnology Ultrasector Profund utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biotechnology Ultrasector's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biotechnology Ultrasector Profund over time as well as its relative position and ranking within its peers.
Biotechnology |
Biotechnology Ultrasector Price To Earning vs. Net Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Ultrasector's current stock value. Our valuation model uses many indicators to compare Biotechnology Ultrasector value to that of its competitors to determine the firm's financial worth. Biotechnology Ultrasector Profund is second largest fund in net asset among similar funds. It is fourth largest fund in price to earning among similar funds . The ratio of Net Asset to Price To Earning for Biotechnology Ultrasector Profund is about 49,350,211 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotechnology Ultrasector's earnings, one of the primary drivers of an investment's value.Biotechnology Price To Earning vs. Net Asset
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Biotechnology Ultrasector |
| = | 116.96 M |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Biotechnology Ultrasector |
| = | 2.37 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Biotechnology Price To Earning Comparison
Biotechnology Ultrasector is currently under evaluation in price to earning among similar funds.
Biotechnology Ultrasector Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Biotechnology Ultrasector, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biotechnology Ultrasector will eventually generate negative long term returns. The profitability progress is the general direction of Biotechnology Ultrasector's change in net profit over the period of time. It can combine multiple indicators of Biotechnology Ultrasector, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The fund invests in financial instruments that the fund advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index represents the biotechnology segment of the SP Total Market Index, which comprises the following sub-industry biotechnology. The fund is non-diversified.
Biotechnology Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Biotechnology Ultrasector. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biotechnology Ultrasector position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biotechnology Ultrasector's important profitability drivers and their relationship over time.
Use Biotechnology Ultrasector in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biotechnology Ultrasector position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotechnology Ultrasector will appreciate offsetting losses from the drop in the long position's value.Biotechnology Ultrasector Pair Trading
Biotechnology Ultrasector Profund Pair Trading Analysis
The ability to find closely correlated positions to Biotechnology Ultrasector could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biotechnology Ultrasector when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biotechnology Ultrasector - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biotechnology Ultrasector Profund to buy it.
The correlation of Biotechnology Ultrasector is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biotechnology Ultrasector moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biotechnology Ultrasector moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biotechnology Ultrasector can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Biotechnology Ultrasector position
In addition to having Biotechnology Ultrasector in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Biotechnology Mutual Fund
To fully project Biotechnology Ultrasector's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Biotechnology Ultrasector at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Biotechnology Ultrasector's income statement, its balance sheet, and the statement of cash flows.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |